Vector-borne pathogens don’t survive by chance, they survive by design. Through immune suppression, antigenic variation, and tissue sequestration, these organisms persist in the host while evading immune clearance and complicating diagnosis.
Vector-borne pathogens don’t survive by chance, they survive by design. Through immune suppression, antigenic variation, and tissue sequestration, these organisms persist in the host while evading immune clearance and complicating diagnosis.
Galaxy Diagnostics and Virginia Tech Unite to Advance Testing for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods When a Test Fails a Patient When diagnostics fail patients, the consequences are real. I’ve lived it. My husband tested negative using the current standard-of-care test for… Continue reading Two LymeX Innovators, One Mission: Better Answers for Patients
Galaxy Diagnostics and Virginia Tech Unite to Strengthen Direct Detection Approaches for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods The Diagnostic Uncertainty Clinicians Face Clinicians evaluating patients with suspected tick-borne disease routinely manage diagnostic uncertainty. Prior exposure, immune variability, and timing-dependent antibody responses can… Continue reading Two LymeX Innovators, One Mission: Advancing Reliable Lyme Diagnostics
When symptoms persist, shift, or contradict standard test results, clinicians need a clearer diagnostic path.
This webinar provides an evidence-informed framework for evaluating elusive vector-borne pathogens that often go undetected in chronic or multisystem presentations.
Vector-borne pathogens don’t survive by chance, they survive by design. Through immune suppression, antigenic variation, and tissue sequestration, these organisms persist in the host while evading immune clearance and complicating diagnosis.
